Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Grows By 14.5%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 222,800 shares, a growth of 14.5% from the December 31st total of 194,600 shares. Based on an average daily volume of 93,700 shares, the short-interest ratio is presently 2.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

DiaMedica Therapeutics Stock Up 2.5 %

Shares of DiaMedica Therapeutics stock traded up $0.15 on Wednesday, hitting $6.13. 65,472 shares of the company were exchanged, compared to its average volume of 77,100. DiaMedica Therapeutics has a 1-year low of $2.14 and a 1-year high of $6.41. The company has a 50-day moving average price of $5.52 and a 200 day moving average price of $4.58. The stock has a market capitalization of $262.12 million, a price-to-earnings ratio of -10.95 and a beta of 1.46.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several large investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd purchased a new position in shares of DiaMedica Therapeutics in the 4th quarter valued at about $81,000. Blue Trust Inc. grew its position in shares of DiaMedica Therapeutics by 56.2% during the fourth quarter. Blue Trust Inc. now owns 69,122 shares of the company's stock worth $375,000 after acquiring an additional 24,875 shares during the last quarter. Geode Capital Management LLC raised its position in DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock valued at $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in DiaMedica Therapeutics during the 3rd quarter worth $40,000. Institutional investors and hedge funds own 10.12% of the company's stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.